Patent · US Active

Bispecific polypeptides against CD137

US12173082B2 · kind B2 · utility

0Cited by

4References

17Claims

0Family size

Assignee

ALLIGATOR BIOSCIENCE AB · SE

Inventors

Eva Dahlen · Lund, SE
Peter Ellmark · Lund, SE
Christina Furebring · Lund, SE
Per Norlen · Lund, SE
Anna Sall · Lund, SE
Laura von Schantz · Lund, SE
Niina Veitonmaki · Lund, SE
Laura Varas · Lund, SE
Jessica Petersson · Lund, SE
Sara Fritzell · Lund, SE

Key dates

Filing date	Sep 23, 2021
Grant date	Dec 24, 2024
Priority date	—
Expiry date	Sep 3, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.